Oral Antipsychotic Medications Starting with "P"
The primary oral antipsychotic medications starting with the letter "P" are paliperidone, perphenazine, and pimavanserin, with paliperidone being the most commonly used in contemporary practice.
Available P-Named Antipsychotics
Paliperidone
- Classification: Second-generation antipsychotic (active metabolite of risperidone)
- Primary indication: Schizophrenia and schizoaffective disorder
- Mechanism: D2 antagonist with 5-HT2A antagonism
- Key consideration: Available in both oral and long-acting injectable formulations 1
- Clinical positioning: Recommended as a potential second-line agent when switching from D2 partial agonists, particularly for persistent positive symptoms 1
Perphenazine
- Classification: First-generation (typical) antipsychotic
- Historical context: Listed among typical agents with an "in-between" side effect profile 2
- Clinical reality: Largely superseded by second-generation agents due to higher risk of extrapyramidal symptoms and tardive dyskinesia
- Current use: Second-line therapy only when patients cannot tolerate or do not respond to atypical agents 2
Pimavanserin
- Classification: Novel atypical antipsychotic
- Unique mechanism: Selective 5-HT2A inverse agonist without significant D2 blockade
- Specific indication: Psychosis associated with Parkinson's disease
- Recent development: Introduced in the last decade as part of novel antipsychotic development 3
Penfluridol (Historical)
- Classification: Long-acting oral antipsychotic (diphenylbutylpiperidine derivative)
- Half-life: 66 hours, allowing once-weekly dosing 4
- Current status: Rarely used in modern practice; primarily of historical interest
Clinical Decision Framework
For acute psychosis/schizophrenia: Paliperidone is the only P-named antipsychotic that should be routinely considered in contemporary practice. It functions as a second-line option when initial treatment with other agents (particularly D2 partial agonists like aripiprazole) has failed 1.
For Parkinson's disease psychosis: Pimavanserin is the specific choice due to its unique mechanism that avoids worsening motor symptoms 3.
Avoid perphenazine unless all second-generation options have been exhausted, given the 50% risk of tardive dyskinesia in elderly patients after 2 years of continuous typical antipsychotic use 2.
Important Caveats
The classification of antipsychotics as "first-generation/typical" versus "second-generation/atypical" is neither pharmacologically valid nor clinically useful for guiding treatment decisions 1. Selection should be based on specific receptor profiles, side effect considerations, and individual patient factors rather than arbitrary generational categories.